The oncological and obstetric results of radical trachelectomy as a fertility-sparing therapy in early-stage cervical cancer patients
-
Published:2022-10-26
Issue:1
Volume:22
Page:
-
ISSN:1472-6874
-
Container-title:BMC Women's Health
-
language:en
-
Short-container-title:BMC Women's Health
Author:
Chen Tao,Li Jia,Zhu Yan,Lu An-Wei,Zhou Li,Wang Jian-San,Zhang Ying,Wang Jun-Tao
Abstract
Abstract
Purpose
This study explored the oncological and obstetric results of radical trachelectomy (RT) in early-stage cervical cancer patients.
Methods
A retrospective analysis was conducted the oncological and obstetric results of 23 patients with early cervical cancer (stages IA2–IB3; International Federation of Gynecology and Obstetrics, 2018) who underwent RT in The Maternal and Child Health Care Hospital of Guiyang, China, from October 2004 to September 2018.
Results
23 patients had cervical tumors of the squamous cell carcinoma histological type. All 23 patients retained reproductive function. The mean follow-up time was 112.87 ± 55.75 (36–199) months. The median tumor size was 2.00 ± 1.35 cm (imperceptible to the eyes 5.00 cm). No recurrence was observed in any of the patient cases. Among the patients with a tumor size > 4 cm (up to 5 cm), three patients who wished to preserve fertility accepted RT following neoadjuvant chemotherapy The pregnancy outcomes were as follows: 8 cases (47.06%) out of 17 cases who attempting pregnancy conceived 12 times.First-trimester abortion and the voluntary abandonment of pregnancy occurred in 4 cases (33.33%), respectively, one patient performed deliberate termination at 24 weeks of gestation. Second-trimester abortion occurred in three cases (25.0%) for chorioamnionitis. Premature delivery at 32 weeks occurred in one case (8.33%).
Conclusion
Radical trachelectomy is a safe and effective treatment for women with early-stage cervical cancer preserving fertility biology. Patients with a cervical tumor sized > 4 cm can be pregnant after neoadjuvant chemotherapy and RT. Accordingly, this treatment is worthy of further exploration.
Funder
Guiyang Health Bureau
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,Reproductive Medicine,General Medicine
Reference32 articles.
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012. INT J CANCER. 2015;136:E359–86. 2. Singh GK, Azuine RE, Siahpush M. Global Inequalities in Cervical Cancer Incidence and Mortality are Linked to Deprivation, Low Socioeconomic Status, and Human Development, International journal of MCH and AIDS, 1 (2012) 17–30. 3. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. EUR J CANCER. 2013;49:3262–73. 4. Li S, Hu T, Lv W, Zhou H, Li X, Yang R, Jia Y, Huang K, Chen Z, Wang S, Tang F, Zhang Q, Shen J, Zhou J, Xi L, Deng D, Wang H, Wang S, Xie X, Ma D, Changes in prevalence and clinical characteristics of cervical cancer in the People’s Republic of China: a study of 10, 012 cases from a nationwide working group, ONCOLOGIST, 18 (2013) 1101–1107. 5. Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. J NATL COMPR CANC NE. 2020;18:660–6.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|